Q4
Mankind Pharma Ltd
Revenue-3.5%
Net Profit+35.2%
OPM26.34%
P&L
Quarterly Consolidated
Revenue
-3.5%3.4K
Expenditure
-4.9%2.9K
Net Profit
+35.2%559.42
NPM 15.73%+38.4%EPS ₹13.44+35.8%
vs Q3 FY26
Mankind Pharma Approves Audited FY26 Financial Results
19 May 2026 · 19 May, 7:32 pm
Summary
Mankind Pharma Limited reported financial updates for Q4 & FY26.
Informational and educational content only. Not investment advice.